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Abstract  
Poly-histidine peptides such H6 (HHHHHH) are used in protein biotechnologies as purification 
tags, protein-assembling agents at the nanoscale and endosomal-escape entities. The 
pleiotropic properties of such peptides make them appealing to design protein-based smart 
materials or nanoparticles for imaging or drug delivery to be produced in form of recombinant 
proteins. However, the clinical applicability of H6-tagged proteins is restricted by the potential 
immunogenicity of these segments. In this study we have explored several humanized 
histidine-rich peptides in tumor-targeted modular proteins than bind and internalize cells 
through the tumoral marker CXCR4. We were particularly interested in exploring how protein 
purification, self-assembling and endosomal escape perform in proteins containing the variant 
histidine-rich tags. Among the tested candidates, the peptide H5E (HEHEHEHEH) has resulted 
promising as a good promoter of endosomal escape of the associated full-length protein upon 
endosomal internalization. The numerical modelling of cell penetration and endosomal 
escape of the tested proteins has revealed a negative relationship between the amount of 
protein internalized into target cells and the efficiency of cytoplasmic release. This fact 
demonstrates that the His-mediated, proton sponge-based endosomal escape saturates at 
moderate amounts of internalized protein, a fact that might be critical for the design of protein 
materials for cytosolic molecular delivery. 
  
Keywords: Protein materials; nanoparticles; genetic design; membrane activity; endosomal 
escape; poly-histidines 
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1. Introduction 
Proteins are versatile macromolecules whose structure and functional capabilities can be 
tailored by conventional genetic engineering. Among other regulatable properties, self-
assembling can be achieved and controlled by protein engineering [1-12]. By either peptide 
synthesis or by recombinant DNA technologies, diverse categories of soft structures, including 
hydrogels, fibers, layers and nanoparticles can be fabricated [13, 14]. Being functional, these 
materials are assuming roles in biomedicine and nanomedicine, for regenerative medicine, 
diagnosis and drug delivery purposes. Protein nanoparticles are of particular interest as 
vehicles for drugs and imaging agents [15]. In this context, gene fusion technologies allow 
recruiting, in a single chain recombinant polypeptide, different functional peptides including 
self-assembling tags, endosomal escape regions and ligands of cell surface receptors [16], 
necessary for nanoparticle formation and for cell-targeted delivery of any associated payload 
drug. The catalogues of receptors and their ligands are rapidly expanding, especially in 
oncology [17], what allows empowering nanoparticles with appropriate cell ligands for 
attachment and cell internalization. The multivalent surface-display of ligands in multimeric 
nanoparticles, formed by multiple building blocks, promotes efficient endosomal 
internalization of the material in a virus-like fashion [18]. A particularly simple engineering 
procedure to generate protein nanoparticles is based on modular building blocks tagged with 
a hexahistidine tag (H6) at the carboxy termini [19, 20], that coordinates divalent cations as a 
molecular cross-linker [21, 22]. The resulting family of oligomers, sizing around 10-30 nm, are 
highly stable in vivo and show an excellent tumor targeting mediated by alternative tumoral 
markers [23, 24] and ligands [25-27]. Because of the excellent biodistribution in mice models 
of human cancers, this category of His-based materials has been used in nanoconjugates or 
protein-only nanoparticles to deliver small molecular weight drugs [28], pro-apoptotic factors 
[29] and toxins [26, 30] in metastatic colorectal cancer, and potent plant cytotoxins in 
metastatic acute myeloid leukaemia [31].  
The peptide H6 is a critical component of such self-assembling platform, not only because of 
its architectonic properties  but also as an endosomolytic agent [32]. The combination of both 
functions is very attractive when designing recombinant protein materials intended for 
endosomal delivery. Importantly, the application of toxin-based nanoparticles, immunotoxins 
or generically, protein-based drug vehicles [33, 34], would largely benefit from potent 
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endosomolytic agents. This is because lysosomal degradation is a critical bottleneck in the 
delivery route [35], and in this context, many strategies and active materials are currently 
developed to enhance the necessary cytosolic delivery [36-40]. Onn the other side, proteins 
are becoming increasingly valuable biopharmaceuticals [34, 41-43], and H6-based 
functionalization by gene fusion is a common procedure [44]. However, the use of H6 in clinics 
might be a source of regulatory concerns, since this peptide might be potentially immunogenic 
in humans [45-47], what pushes to identify alternatives regarding both the nanoarchitectonic 
and endosomolytic properties of H6. 
 
2. Materials and methods 
2.1 Protein production and purification 
Histidine-carrying modular proteins derived from the parental T22-GFP-H6 (30.69 kDa, Figure 
1), and the histidine-rich (Hn) sequences used here have a human origin (see Table 1). Further 
details of these proteins can be found elsewhere [48]. E. coli Origami B (BL21, OmpT-, Lon-, 
TrxB, Gor-; Novagen) transformed cells were then grown at 37 ºC overnight in LB (Lysogeny 
Broth) and the encoded proteins were produced at 20 ºC overnight by induction of gene 
expression with 0.1 mM of Isopropyl-β-D-thiogalactopyronaside (IPTG) at an OD550 of 0.5-0.7. 
Cells were harvested by centrifugation for 15 min (5,000g at 4 ºC) and pellets stored at -80ºC.  
Before use, pellets were then thaw and resuspended in Wash buffer (20 mM Tris, 500 mM 
NaCl, pH = 8) with protease inhibitors (Complete EDTA-free; Roche Diagnostics). Cell 
disruption was performed by three rounds of sonication (0.5-on, 0.5-off for 5 min) at 10 % of 
amplitude (Branson Digital Sonifier®) and the soluble fraction separated by centrifugation for 
45 min (15.000g at 4ºC), and further filtered in pore diameters of 0.45 followed by 0.22 m.  
Proteins were purified by Immobilized Metal Affinity Chromatography (IMAC) in an ÄKTA pure 
system (GE Healthcare) using HiTrap Chelating 5 mL columns (GE Healthcare). Protein elution 
was performed by a linear gradient of Elution buffer (20 mM Tris, 500 mM NaCl, 500 mM 
Imidazole, pH = 8) and eluted protein dialyzed against sodium carbonate (166 mM NaCO3H, 
pH = 8) either-or sodium carbonate with salt (166 mM NaCO3H, 333 mM NaCl, pH = 8) buffers.  
 
Protein purity, integrity and concentration, and nanoparticle formation 
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Protein purity was checked by Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) and Western Blot (WB) immunoassay by using a 1/500 dilution of anti-GFP 
monoclonal antibody (Santa Cruz Biotechnology). Protein concentration was determined by 
Bradford’s assay, and integrity evaluated by Matrix-Assisted Laser Desorption Ionization Time-
of-Flight (MALDI-TOF) mass spectrometry. The formation of protein nanparticles was assessed 
by determining the volume size distribution by dynamic light scattering at 633 nm and 25 °C 
in a Zetasizer Nano ZS (Malvern Instruments Limited). For that, ZEN2112 3 mm quartz batch 
cuvettes were used in triplicate readings for error estimation, filled with protein samples in 1 
mg/mL in carbonate buffer as described above. 
 
Protein internalization and endosomal escape  
HeLa CXCR4+ cells were cultured in 24-well plates (60,000 cells/well during 24h for different 
time/concentration assays. 30,000 HeLa cells/well were cultured during 48 h for chloroquine 
and AMD competition), in all cases using MEM Alpha 1x GlutaMAXTM medium (Gibco) 
supplemented with foetal bovine serum (FBS) at 37ºC in a 5 % CO2 humidified atmosphere, 
reaching a confluence of 70 %. Protein internalization was monitored by determining the cell 
green fluorescence after a harsh trypsin treatment at different exposure times. After 
exposure, cells were detached and externally attached protein removed by adding Trypsin-
EDTA (Gibco®) at 1 mg/mL for 15 min and 37ºC. This is a particularly harsh trypsin treatment 
specifically developed to degrade cell surface-attached (but not internalized) protein, and 
aimed to prevent artefact readings by the contamination of externally attached fluorescent 
material [49]. Intracellular protein fluorescence was then determined by flow cytometry using 
a FACS-Canto system (Becton Dickinson) at 15 mW with an air-cooled argon ion laser exciting 
at 488 nm and corrected by the intrinsic fluorescence emission of each protein.  Quantitative 
data are expressed as mean ± standard error. Additionally, the specific CXCR4-mediated 
protein internalization was probed by the addition of a CXCR4 antagonist (AMD3100) [50, 51], 
that blocks the interaction between T22 (MRRWCYRKCYKGYCYRKCR) and CXCR4. This 
compound was added at a final concentration of 500 nM (1:10 protein ratio) for 1 h prior 
protein incubation at 50 nM. Furthermore, the endosomal escape capacity of proteins was 
assessed by adding an inhibitor of endosomal acidification (chloroquine) at a final 
concentration of 100 µM (1:100 protein ratio) for 4 h prior protein incubation at 1000 nM. 
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OptiPROTM SFM medium supplemented with L-glutamine was used for compound dilution and 
protein incubation. Since CQ prevents endosomal acidification and subsequent lysosomal 
formation in 4 h-experiments, the total amount of protein able to internalize and to reach the 
cell cytoplasm can be determined (+CQ). While comparing these values with the ones in 
absence of the drug (-CQ), the percentage of non-degraded protein (tagged as endosomal 
escape) can be calculated as % endosomal escape = (-CQ*100)/(+CQ). Those numbers are 
indicated on top of plot bars in Figure 1.  
 
Fluorescence emission 
GFP fluorescence emission was determined at 510 nm using an excitation wavelength of 488 
nm with a Varian Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies). Before 
measuring, proteins were equally diluted in their corresponding sodium carbonate w/o salt 
buffers to 1 mg/mL in a final volume of 100 µL.  
 
Confocal imaging 
HeLa CXCR4+ cells were cultured in MatTek (MatTek Corporation) plates (60.000 cells/well 
during 24h) using MEM Alpha 1x GlutaMAXTM medium (Gibco) supplemented with fetal bovine 
serum (FBS) at 37ºC in a 5 % CO2 humidified atmosphere and exposed to 1 µM of soluble 
protein for 24h. Cell nuclei were then labelled with Hoechst 33342 (ThermoFisher) at 5 µg/mL, 
displaying blue signal and plasma membranes with CellMask™ Deep Red (ThermoFisher) at 
2.5 µg/mL displaying red signal, both incubated for 10 min at room temperature. Cells were 
then washed in phosphate saline buffer (Sigma-Aldrich) and images collected on an inverted 
TCS SP5 Spectral confocal microscope (Leica Microsystems) using 63× (1.4 NA) oil immersion 
objective lens. Hoechst 33342 excitation was reached via 405 nm blue diode laser, CellMaskTM 
Deep Red via 633 nm line of a HeNe laser and GFP via 488 nm line of an argon ion laser. 
Interchannel crosstalk was avoided by configuring emission detection bandwidths, confocal 
pinhole set to 1 Airy unit and z-stacks acquisition intervals chosen to satisfy Nyquist sampling 
criteria. Multitrack sequential acquisition was used during the procedure and images analyzed 
by using Imaris v 7.2.1 software (Bitplane).  
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3. Results 
We have explored how several variants of Hn peptides in cell-targeted protein nanoparticles 
would perform regarding cell penetrability and endosome membrane activity. They derive 
from the parental T22-GFP-H6, a fusion protein that assembles as nanoparticles of 12 nm, that 
have been used for precision delivery of chemical drugs [28] and protein toxins [29, 30] into 
CXCR4+ tumor cells. Targeting is provided by the end-terminal peptide T22, a potent ligand of 
CXCR4 that promotes endosomal internalization [25]. To explore the impact of Hn in self-
assembling, the H6 end-terminal peptide in T22-GFP-H6 had been replaced by the alternative 
histidine-rich peptides of similar length H3A, H5T and H5E, corresponding to HAAHAH, 
HTHTHTHTH and HEHEHEHEH amino acid sequences respectively. These peptides show at 
least 90 % of homology to sequences of human origin (Table 1), and as in the case of T22-GFP-
H6, they also promote the spontaneous formation of nanoparticles ranging from 10 to 18 nm 
[48]. In this context, we have comparatively characterized the Hn variant nanoparticles, 
namely T22-GFP-H3A, T22-GFP-H5T, T22-GFP-H5E and T22-GFP-H6 (Figure 1A inset, Table 1) 
regarding their interactivity with target CXCR4+ HeLa cells. No cell toxicity was observed in any 
of these materials upon exposure (Figure 1A), while all nanoparticles showed a comparable 
level of cell penetrability (Figure 1B). Uptake was, in all cases, dependent on the specific 
interaction of T22 with CXCR4, since the CXCR4 antagonist inhibited internalization with only 
a very low level of variability (from 95.5 % to 97.2 %, Figure 1C). At that point, endosomal 
escape was explored by using chloroquine (CQ), that prevents acidification and lysosomal 
protein degradation [40, 52]. The extent in which CQ enhances the fluorescence level is 
indicative of poor endosomal escape, while a null effect of the drug on the fluorescence would 
be indicative of a complete endosomal escape of the protein material. The addition of QC to 
CXCR4+ HeLa cells in culture, before exposure to protein nanoparticles, showed a clearly 
differential impact on the intracellular fluorescence (Figure 1D), indicating a distinguishable 
membrane activity of Hn variants. In Figure 1 E, representative images of HeLa cells exposed 
to nanoparticles are shown, highlighting the endosomal route of cell penetration. 
Because of such observed impact, we explored how the endosomal escape of the variant 
nanoparticles could be dependent on the number of histidine residues in the Hn tag. For that, 
we analyzed previously obtained physicochemical data on T22-GFP-H6 and T22-GFP-H5T, and 
we fully characterized T22-GFP-H3A and T22-GFP-H5E (Supplementary Table 1). All data sets 
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were plotted versus the number of histidine residues in the Hn tags and plotted to evaluate 
potential correlations. As observed, cell internalization (Figure 2A) and endosomal escape 
(Figure 2B) were not dependent on the number of histidine residues, being these parameters 
probably influenced by features of the Hn tags less apparent than the histidine residue 
number. As an expected positive control, the amount of imidazole necessary for the elution 
of fusion proteins in His-based chromatographic purification was largely dependent on the Hn 
value (Figure 2C). Interestingly, when plotting endosomal escape versus internalization, an 
unexpected but clear negative dependence was observed (Figure 2D). This observation might 
presumably reveal a general relationship between the receptor-dependent uptake of protein 
materials at the cell surface level and their ability to be released in the cytoplasm from 
uptaking vesicles.  The possibility to unveil a generic mechanism in the cell penetrability of 
nanoparticles prompted us to further explore the endosome escape mechanisms of the Hn 
proteins, for what both internalization and endosomal escape were numerically modelled. 
The model [53] that regulates the intensity of intracellular fluorescence 𝑓(𝑡) is 
      
𝑑𝑓
𝑑𝑡
= 𝑘(𝐿 − 𝑓), 𝑓(0) = 0, 0 < 𝑓 < 𝐿  ⟹ 𝑓(𝑡) = 𝐿(1 − 𝑒−𝑘𝑡)   (1) 
where  𝑘 is the permeability of the cell membrane to the fluorescent proteins, and the 
fluorescence half-life 𝜏 =
𝑙𝑛 2
𝑘
 is the proteolytic stability of the material (determined by its 
fluorescence).  The typical evolution of  𝑓(𝑡) and  
𝑑𝑓
𝑑𝑡
 is displayed in Figures 3 A, B, where the 
blue line is for non-treated cells, the red line is for chloroquine-treated cells, and the green 
line measures the decay of fluorescence. 
The initial rate of intracellular fluorescence rising is 𝑣 ≡ (
𝑑𝑓
𝑑𝑡
)
𝑡=0
= 𝑘𝐿. Then, the fluorescence 
half-life can also be obtained as 
𝜏 =
ln 2 𝐿
𝑣
     (2) 
The addition of chloroquine, that minimizes lysosomal proteolysis of the material, affects 
both 𝑘 and 𝐿, and then, intracellular fluorescence evolves as described in the following 
differential approach 
 𝑑𝑓 =
𝜕𝑓
𝜕𝐿
𝑑𝐿 +
𝜕𝑓
𝜕𝑘
𝑑𝑘 = 𝑓 𝑑 𝑙𝑛 𝐿 +
1
2
(𝐿 − 𝑓)𝑑𝑘2   (3) 
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In the beginning, for 𝑓 → 0, the dominant term is accounted by the variation of 𝑘, namely 
𝑑𝑓 ≈
1
2
𝐿 𝑑𝑘2. When 𝑓 → ∞, the dominant term is accounted by the variation of 𝐿, namely 
𝑑𝑓 ≈ 𝐿 𝑑 𝑙𝑛 𝐿 = 𝑑𝐿. During the experimental time, 𝑓 increases and the factor  
1
2
(𝐿 − 𝑓) 
decreases. Hence the first one will be prevalent. Their quotient 
2𝑓
𝐿−𝑓
  grows very fast and tends 
to 1 when 
    2𝑓 = 𝐿 − 𝑓 ⟹ 𝑓 =
1
3
𝐿 ⟹ 𝑡 =
𝑙𝑛
3
 2
𝑙𝑛 2
 𝜏 = 0.4055 𝜏 
Then, much earlier than for time 𝑡 = τ the first term becomes dominant. Furthermore, in the 
experimental data, the values  𝑑 𝑙𝑛 𝐿 ∼ Δ 𝑙𝑛 𝐿 are always greater than the values 𝑑𝑘2 ∼ Δ𝑘2.  
The experimental data of chloroquine-treated cells (labelled with prime) are taken as 
reference. Then, we always obtain, as seen in Supplementary Figure 1A, 
ln L − ln L′ < 0 ⟺ 𝐿 < 𝐿′ 
𝑘2 − 𝑘′2 > 0 ⟺ 𝜏 < 𝜏′ 
It would be expected that at early times, before the proteolytic protective effects of 
chloroquine occur, the initial penetration rate would be the same in absence and in presence 
of the drug, 
    𝑣 = 𝑘𝐿 = 𝑣′ = 𝑘′𝐿′ ⟺
𝐿
𝐿′
=
𝑘′
𝑘
=
𝜏
𝜏′
    (4) 
The plot in Supplementary Figure 1B indicates that this is nearly (but not completely) the case. 
It must be noted that the quotient 
𝑣
𝑣′
= 1 is lost in samples with the highest relative variation 
of fluorescence 
𝐿
𝐿′
 (Supplementary Figure 1C). Also, the proportionality of Eq. (2) is similar 
when comparing all samples (Figure 3A, right), but it is lost for high values of 𝐿.  
In summary, the inverse relationship Eq. (4) between 
𝐿
𝐿′
 and fluorescence 
𝑘
𝑘′
 is accomplished 
(Supplementary Figure 2A), and there is a clear negative correlation between the decrease of 
fluorescence and 𝐿 in chloroquine-treated cultures (Supplementary Figure 2B). Finally, the 
half-live growth is reduced when 𝐿 increases (Supplementary Figure 1C). Interestingly, 𝑣 = 𝑘𝐿 
is nearly constant in absence and in presence of chloroquine, indicating that the drug acts 
predominantly at late endosome stages, and only in a residual (but detectable) way at early 
internalization phases.  
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The value 𝑎 = 0.8634 obtained in the fitting 𝐿 − 𝐿′ = 𝑎𝐿′ (Supplementary Figure 2B) is 
coincident with the slope shown in the Figure 2D. This fully supports the concept that 
endosomal escape mediated by histidine residues is specially favored when low amounts of 
materials are internalized by cells. On the contrary, cytosolic penetrability is inhibited, in 
relative terms, in the case of highly effective cell penetrating nanoparticles, indicating a 
saturation mechanism in the endosomal release of engulfed nanoparticles. As this fact has 
been profiled by the whole set of Hn-carrying materials it might reflect a general law that at 
least should be valid for His-mediated endosomal escape processes of protein nanoparticles.   
 
4. Discussion 
The peptide H6 is a widely spread tags for the one-step purification of recombinant proteins 
through Ni2+-based affinity chromatography [46, 54]. Upon purification, the presence of H6 or 
related peptides in the final protein product might have unexpected biological impacts, such 
as aberrant biodistribution of the protein or protein complex upon systemic injection [55, 56]. 
In this context, and also envisaging potential immunoreactions in protein materials intended 
for clinical use, the removal of H6 from purified proteins would be a desirable biotechnological 
step [44]. However, in the biological fabrication of protein-based materials, Hn peptides show 
interesting roles as architectonic tags as metal-dependent cross-molecular binders [12, 57, 
58]. H6 has been efficiently used to force the formation of protein nanoparticles [59, 60], 
designed to transport either small molecular drugs [61] or cytotoxic proteins in cancer 
therapies [26, 31, 62]. In addition, and facing lysosomal degradation as a major bottleneck in 
the delivery of protein nanoparticles [40], Hn peptides offer an added value to protein 
supramacromolecular complexes for intracellular delivery. In contrast to other diverse 
pathways of endosomal escape [40, 63], Hn peptides promote endosomal escape of 
macromolecules and complexes by a proton-sponge mechanism [40], that has not been so far 
investigated in deep. To combine the appealing properties of Hn peptides regarding protein 
purification, nanoparticle formation and endosomal escape, limiting potential immunotoxicity 
risks, we have explored the performance of several human or human-like Hn peptides, 
previously explored as not immunogenic (Table 1 and references therein), regarding their 
ability to promote endosomal escape. In form of T22-GFP-Hn constructions, targeted to 
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CXCR4+ cells through T22 [23], the four tested Hn segments are not cytotoxic, penetrate target 
cells with high level of CXCR4-dependence (then, by an endosomal route), and respond 
differentially to the presence of chloroquine (Figure 1), that prevents lysosomal destruction 
[52]. In particular, T22-GFP-H5E promotes an important endosomal escape slightly higher 
(23.66 %) than that triggered by H6 (Figure 1). Even if the efficacy of H5E as an endosomolytic 
agent is not dramatically higher than that H6, the discovery of a humanized Hn version that 
performs slightly better than H6 in cytosolic delivery exemplifies the potential of optimized 
histidine tails to promote endosomal escape. In addition, the peptide HEHEHE does not 
promote hepatic accumulation of associated polypeptides [56, 64], probably because of its 
hydrophilic nature when compared to similar Hn constructs [65].  
 
As a side observation, we demonstrate that the presence of chloroquine enhances the 
intracellular permanence of uptaken proteins. Since chloroquine inhibits acidification of 
endocytic vesicles [66] and the only type of endocytic vesicles that undergo acidification is 
that based on clathrin [67], the experimental data presented here strongly support that T22-
empowered GFP-based nanoparticles exploit the clathrin-endosomal route for internalization. 
Interestingly, all T22-GFP-Hn particles bind specifically the cytokine receptor CXCR4 for cell 
internalization, as the CXCR4 antagonist AMD3100 blocks their entrance (Figure 1 C). Also, 
CXCR4 is also used by the Human Immunodeficiency Virus as a co-receptor for cell infection 
[68], and this virus enters cells via clathrin-mediated endocytosis [69]. Altogether, these data 
indicate that binding to CXCR4 favors consequent internalization by the clathrin-endosomal 
route.  
In a more transversal context, when comparing the endosomal escape of the proteins 
(inversely correlating with the increase of intracellular fluorescence mediated by chloroquine) 
with the intensity of intracellular fluorescence, it rendered an unexpected negative correlation 
(Figure 2D). This fact was fully confirmed by an accurate dynamic modeling of the intracellular 
fluorescence upon exposure to the fluorescent proteins (Supplementary Figure 2). This 
analysis strongly supports the concept that endosomal escape, as mediated by Hn peptides, 
is saturated at moderated amounts of internalized protein, what has critical implications in 
the design of nanoscale protein materials for intracellular drug delivery. For protein drugs [33, 
43], that are intrinsically sensitive to lysosomal destruction, developing agents to enhance cell 
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penetrability might be then result in a nonlinear gain in cytosolic delivery. However, regarding 
protein-drug conjugates, in which the effective drug is resistant to lysosomal activities, higher 
cell internalization should result in higher drug activity. Irrespective of that, we have here 
identified a set of humanized His-rich peptides that can be used as substitutes of H6 when 
engineering endosomal escape, which sufficiently keep the functionalities of H6 during 
chromatographic purification of recombinant proteins.   
 
5. Conclusions 
We have demonstrated here that humanized His-rich segments, with a number of His residues 
below 6, can efficiently promote endosomal escape of modular proteins targeted to CXCR4+ 
cells. In particular, the peptide HEHEHEHEH, appears as a promising tool to favor the 
intracellular trafficking and the proteolytic stability of the cargo protein, while it keeps the 
functional binding to Ni2+. The intensity of endosomal escape promoted by a series of 
humanized Hn peptides negatively correlates with the amount of internalized protein, 
revealing a saturation mechanism in the Hn-mediated cytosolic penetration. Finally, 
chloroquine, that mainly acts at the level of late endosomes, has a residual effect on the first 
stages of protein uptake, slightly enhancing the velocity of cellular penetration at the early 
endosome stages. 
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Figure 1. Cell interactivity of Hn-carrying protein nanoparticles. A. Cytotoxicity of Hn protein 
nanoparticles (at 2 µM) on CXCR4+ HeLa cells upon 48 h of exposure. Numbers indicated on top of plot 
bars represent cell viability in percentage regarding the control cell culture. In the inset, schematic 
representation of protein modular distribution. N=3. B. Internalization of protein nanoparticles added 
to 50 or 1000 nM for 1 and 24 h in CXCR4+ HeLa cell cultures. Data on H6 and 5HT were published 
previously [48]. N=2. C. Inhibition of protein uptake (added to 50 nM for 24 h) by the CXCR4+ antagonist 
AMD3100 at 500 nM, after 1 h of exposure. Numbers indicated on top of plot bars represent 
percentage of internalization upon AMD addition. Data on H6 and H5T were published previously [48]. 
N=2. D. Internalization and endosomal escape of protein nanoparticles (added to 1 µM for 24 h) in 
CXCR4+ HeLa cells upon chloroquine (CQ) addition. CQ was used to prevent endosomal acidification at 
100 µM for 4 h. Numbers indicated on top of plot bars represent the estimated endosomal escape of 
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the uptake material, in percentage. N=2. E. Confocal sections of CXCR4+ HeLa cells 24h of exposure to 
different nanoparticles. Membranes are labelled in red, the nuclear section in blue, and the green 
signal is the natural fluorescence of the assembled GFP. Arrows indicate yellowish emission, resulting 
from red and green merging into endosomal compartment. 
 
 
 
Figure 2. Impact of the His number of the Hn tag on cell interactivity. Correlation between the number 
of histidine residues in the Hn tag with cell internalization (A), endosomal escape (B) and eluting 
amount of imidazole (C). In D, endosomal escape versus internalization is plotted. Data sets used 
represented here are shown in Supplementary Table 1.  
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Figure 3. Variation of intracellular fluorescence. A. Dynamics of intracellular fluorescence. The 
saturation values is L. The initial increase is greater with higher values of k. B. Velocity of variation of 
intracellular fluorescence. The initial value is 𝑣 = 𝑘 𝐿. 
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Table 1. Homology between selected His-rich sequences and human (Homo sapiens) proteins.   
a Underlined amino acid sequences are those matching in the FASTA search. Flanking sequences (three residues 
each end) are also indicated together with the original amino acid numbering of the protein. 
b Hydrodynamic diameter of the resulting nanoparticles was previously determined (Table 1 in [48]) and 
confirmed here by DLS. 
H-rich 
peptide 
BLAST protein 
Uniprot 
code 
Subcellular 
localization and/or 
function 
FASTA sequence a 
 
Nanoparticle 
size (nm) b 
-H6 
 (HHHHHH) 
 
Histidine-rich 
carboxyl terminus 
protein 1 
Q6UXD1 
Single-pass 
membrane protein 
...85VGLHHHHHPRHTP
HHLHHHHHPHR108... 
 
 
Ubiquitin 
carboxyl-terminal 
hydrolase 34 
Q70CQ2 Cytosolic protein 
...746GPQHHHHHHHHH
HHHDGH763... 
 
 
 
11.7 ± 0.01 
Voltage-
dependent P/Q-
type Calcium 
channel subunit 
alpha-1A 
O00555 
Multi-pass 
membrane protein 
...2207HRQHHHHHHHH
HHPPP2222... 
 
Angiomotin Q4VCS5 
Cell surface 
transmembrane 
protein 
...382QQQHHHHHHHQ
QQ394... 
 
-H3A 
(HAAHAH) 
Thrombospondin 
type-1 domain-
containing 
protein 7B 
Q9C0I4 
Single-pass 
membrane protein 
type-1 
...27LLSHAAHLEG36... 
 
 
 
18.1 ± 0.00 
Biotinidase P43251 
Extracellular or 
secreted protein 
...1MAHAHIQG8... 
 
-H5T 
(HTHTHTHTH) 
Fibroblast growth 
factor receptor-
like 1 
Q8N441 
Single-pass 
membrane protein 
type-1    
...476TDIHTHTHTHSHT48
8... 
 
Tumor 
differentiation 
factor 
Q6T424 Excreted protein 
...23QDTHTHTHTHTHT
HTHTNT41... 
10.1 ± 0.01 
-H5E 
(HEHEHEHEH) 
Neuroendocrine 
secretory protein 
55 
O95467 
Multi-pass 
membrane protein 
...83ESDHEHEEAD92... 
 
Zinc transporter 
ZIP9 
Q9NUM
3 
Multi-pass 
membrane protein 
...90SVVHEHEHSHD100... 
 
10.9 
± 0.04 
Repetin protein Q6XPR3 
Multi-pass 
membrane protein 
...745RQTHEHEQSH754... 
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